JP2021505620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505620A5 JP2021505620A5 JP2020531164A JP2020531164A JP2021505620A5 JP 2021505620 A5 JP2021505620 A5 JP 2021505620A5 JP 2020531164 A JP2020531164 A JP 2020531164A JP 2020531164 A JP2020531164 A JP 2020531164A JP 2021505620 A5 JP2021505620 A5 JP 2021505620A5
- Authority
- JP
- Japan
- Prior art keywords
- arginase
- human
- subject
- use according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004452 Arginase Human genes 0.000 claims 11
- 108700024123 Arginases Proteins 0.000 claims 11
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 claims 11
- 102000053089 human ARG1 Human genes 0.000 claims 11
- 101710129000 Arginase-1 Proteins 0.000 claims 10
- 102100021723 Arginase-1 Human genes 0.000 claims 10
- 230000037396 body weight Effects 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 229910017052 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023199616A JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594747P | 2017-12-05 | 2017-12-05 | |
| US62/594,747 | 2017-12-05 | ||
| US201862725612P | 2018-08-31 | 2018-08-31 | |
| US62/725,612 | 2018-08-31 | ||
| US201862745000P | 2018-10-12 | 2018-10-12 | |
| US62/745,000 | 2018-10-12 | ||
| PCT/US2018/063982 WO2019113157A1 (en) | 2017-12-05 | 2018-12-05 | Method and composition for treating arginase 1 deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023199616A Division JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021505620A JP2021505620A (ja) | 2021-02-18 |
| JP2021505620A5 true JP2021505620A5 (enExample) | 2022-01-11 |
Family
ID=64734275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531164A Pending JP2021505620A (ja) | 2017-12-05 | 2018-12-05 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
| JP2023199616A Pending JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023199616A Pending JP2024028760A (ja) | 2017-12-05 | 2023-11-27 | アルギナーゼ１欠損症を治療するための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11717562B2 (enExample) |
| EP (1) | EP3720476A1 (enExample) |
| JP (2) | JP2021505620A (enExample) |
| KR (1) | KR20200122298A (enExample) |
| CN (3) | CN120643682A (enExample) |
| AU (1) | AU2018378485B2 (enExample) |
| CA (1) | CA3084801A1 (enExample) |
| MX (2) | MX2020005933A (enExample) |
| TW (1) | TWI878212B (enExample) |
| WO (1) | WO2019113157A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3449935A1 (en) * | 2017-08-31 | 2019-03-06 | Erytech Pharma | Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency |
| EP3866837A1 (en) * | 2018-10-19 | 2021-08-25 | AERase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| WO2021041904A1 (en) | 2019-08-30 | 2021-03-04 | Aeglea Biotherapeutics, Inc. | Methods for production of human recombinant arginase 1 and uses thereof |
| CN114196712B (zh) * | 2021-11-30 | 2024-04-02 | 新泰市佳禾生物科技有限公司 | 一种固定化酶法生产l-鸟氨酸的方法 |
| CN114350721B (zh) * | 2021-11-30 | 2024-05-24 | 新泰市佳禾生物科技有限公司 | 微生物酶法生产l-鸟氨酸的方法 |
| CN114214353B (zh) * | 2021-11-30 | 2023-07-18 | 新泰市佳禾生物科技有限公司 | 一种发酵生产人重组精氨酸酶i的方法 |
| CN116179452A (zh) * | 2022-07-11 | 2023-05-30 | 山东第一医科大学(山东省医学科学院) | 一种用于治疗精氨酸酶缺乏症的工程益生菌及其构建方法和应用 |
| WO2025171346A1 (en) * | 2024-02-08 | 2025-08-14 | University Of Florida Research Foundation, Incorporated | Indoleamine 2,3-dioxygenase variants |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02117383A (ja) | 1988-10-26 | 1990-05-01 | Tosoh Corp | ヒトアルギナーゼの製造方法 |
| US5780286A (en) | 1996-03-14 | 1998-07-14 | Smithkline Beecham Corporation | Arginase II |
| WO2003063780A2 (en) | 2002-01-25 | 2003-08-07 | Cancer Treatments International | Therapeutic composition for treatment of cancer by arginine depletion |
| HK1053577A2 (en) | 2002-06-20 | 2003-10-10 | Bio-Cancer Treatment International Limited | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| GB0315248D0 (en) * | 2003-06-30 | 2003-08-06 | Hoffmann La Roche | HCV regulated protein expression |
| FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
| CN1745847A (zh) | 2004-09-08 | 2006-03-15 | 康达医药科技有限公司 | 用精氨酸酶治疗肝炎的药物组合物和方法 |
| DE602006019916D1 (de) | 2005-12-12 | 2011-03-10 | Canji Inc | Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase |
| US8440184B2 (en) | 2008-10-31 | 2013-05-14 | Gma Technologies Llc | Compositions of engineered human arginases and methods for treating cancer |
| US9382525B2 (en) * | 2009-03-26 | 2016-07-05 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| US8679479B2 (en) | 2009-06-29 | 2014-03-25 | Aerase, Inc. | Methods for purifying pegylated arginase |
| WO2012061015A2 (en) | 2010-11-03 | 2012-05-10 | Scott & White Healthcare | L-citrulline supplementation during arginine depletion therapy with arginase |
| CN103184209B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用 |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| FR3005420B1 (fr) | 2013-05-07 | 2015-09-18 | Erytech Pharma | Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues. |
| PT3105328T (pt) | 2014-02-11 | 2020-07-06 | Univ Colorado Regents | Engenharia de genomas multiplexada possibilitada por crispr |
| CA2944903A1 (en) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| CN106456723B (zh) * | 2014-04-29 | 2021-03-09 | 康达医药科技有限公司 | 采用精氨酸酶i调节免疫系统的方法和组合物 |
| EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
| ES2727137T3 (es) | 2014-08-28 | 2019-10-14 | Halozyme Inc | Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario |
| EP3416976A2 (en) | 2016-02-16 | 2018-12-26 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
| KR102646323B1 (ko) * | 2016-05-06 | 2024-03-13 | 이뮤노포지 주식회사 | 제어된 지속 방출을 위한 elp 융합 단백질 |
-
2018
- 2018-12-05 TW TW107143773A patent/TWI878212B/zh active
- 2018-12-05 CN CN202510809272.4A patent/CN120643682A/zh active Pending
- 2018-12-05 WO PCT/US2018/063982 patent/WO2019113157A1/en not_active Ceased
- 2018-12-05 CN CN201880079119.9A patent/CN111787941A/zh active Pending
- 2018-12-05 US US16/210,248 patent/US11717562B2/en active Active
- 2018-12-05 CA CA3084801A patent/CA3084801A1/en active Pending
- 2018-12-05 KR KR1020207019283A patent/KR20200122298A/ko not_active Ceased
- 2018-12-05 CN CN202510809152.4A patent/CN120661640A/zh active Pending
- 2018-12-05 AU AU2018378485A patent/AU2018378485B2/en active Active
- 2018-12-05 EP EP18821957.0A patent/EP3720476A1/en active Pending
- 2018-12-05 MX MX2020005933A patent/MX2020005933A/es unknown
- 2018-12-05 JP JP2020531164A patent/JP2021505620A/ja active Pending
-
2020
- 2020-07-13 MX MX2025006207A patent/MX2025006207A/es unknown
-
2023
- 2023-06-29 US US18/344,083 patent/US20240009284A1/en active Pending
- 2023-11-27 JP JP2023199616A patent/JP2024028760A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505620A5 (enExample) | ||
| USRE47233E1 (en) | Albumin-binding arginine deiminase and the use thereof | |
| US20140220636A1 (en) | PHAGE &phgr;MRU POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF | |
| JP2021502980A5 (enExample) | ||
| CA3073317A1 (en) | Engineered dnase enzymes and use in therapy | |
| NZ603813A (en) | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases | |
| JP2012519489A5 (enExample) | ||
| JP2008508859A5 (enExample) | ||
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2010533478A5 (enExample) | ||
| Voulgari et al. | Infliximab therapy in established rheumatoid arthritis: an observational study | |
| Ritchie et al. | Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond | |
| Elsayed et al. | Nephrotoxicity of cefepime: A new cephalosporin antibiotic in rats | |
| WO2012096411A1 (ja) | 難治性炎症性腸疾患の予防又は治療方法 | |
| Keary et al. | Characterization of a bacteriophage-derived murein peptidase for elimination of antibiotic-resistant Staphylococcus aureus | |
| JP2015535237A5 (enExample) | ||
| Su et al. | Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance | |
| JP2008528512A5 (enExample) | ||
| JP2018500341A5 (enExample) | ||
| KR20160108560A (ko) | 신규 치료 | |
| US12104186B2 (en) | Deimmunized lysostaphin and methods of use | |
| CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
| CN110117587A (zh) | 一种葡萄球菌裂解酶及其保存方法和应用 | |
| JP2008512399A5 (enExample) | ||
| JP2019513138A5 (enExample) |